Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 5/20 | 0.88 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.88 |
| ▸ | NAMPT | P43490 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.47 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.46 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1966284 | 1.00 | MTNR1A (0.88) | MTNR1AMTNR1BNAMPTSIGMAR1NPY5R | |
| SCHEMBL10324092 | 0.93 | MTNR1B (1.00) | MTNR1AMTNR1BNAMPTSIGMAR1NPY5R | |
| SCHEMBL10324093 | 0.93 | MTNR1B (1.00) | MTNR1AMTNR1BNAMPTSIGMAR1NPY5R | |
| SCHEMBL1967518 | 0.89 | MTNR1A (0.83) | MTNR1AMTNR1BSIGMAR1NPY5RLMNA | |
| SCHEMBL1964369 | 0.89 | MTNR1A (0.83) | MTNR1AMTNR1BSIGMAR1NPY5RLMNA | |
| SCHEMBL1966352 | 0.83 | MTNR1B (0.74) | MTNR1AMTNR1BSIGMAR1NPY5RLMNA | |
| SCHEMBL1966354 | 0.83 | MTNR1B (0.74) | MTNR1AMTNR1BSIGMAR1NPY5RLMNA | |
| SCHEMBL1965545 | 0.83 | MTNR1A (0.73) | MTNR1AMTNR1BSIGMAR1NPY5RSMPD3 | |
| SCHEMBL1965540 | 0.83 | MTNR1A (0.73) | MTNR1AMTNR1BSIGMAR1NPY5RSMPD3 | |
| SCHEMBL1966836 | 0.82 | MTNR1B (0.72) | MTNR1AMTNR1BNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120184594-A1 | PHENYLPYRROLIDINE COMPOUNDS | FERRER INTERNACIONAL S.A. (ES) | 2012-07-19 | — | — | US | claimed |
| EP-2203422-B1 | PHENYLPYRROLIDINE COMPOUNDS | FERRER INT (ES) | 2011-06-22 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184594-A1 | PHENYLPYRROLIDINE COMPOUNDS | MTNR1A, MTNR1B, MC4R | MTNR1A 1/4885MTNR1B 2/4885NAMPT 314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.